Nemus Bioscience announced an agreement with AMRI for the development and manufacture of Nemus’ proprietary cannabinoid-based active pharmaceutical ingredients (API).
The agreement will capitalize on AMRI’s process chemistry expertise in the synthesis and formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus’ compound in development for the treatment of glaucoma.
Headquartered in Long beach, California (USA), Nemus Bioscience is focused on the discovery, development, and commercialization of cannabinoid-based therapeutics. Utilizing certain proprietary technology licensed from the University of Mississippi, Nemus is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. Nemus’ strategy is to explore the use of synthetic compounds, alone or in combination with developmental partners.
AMRI is a global contract research and manufacturing organization with locations in North America, Europe and Asia. Its key business segments include Discovery and Development Services, Active Pharmaceutical Ingredients, and Drug Product Manufacturing.